Cipla Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Efficient capital deployment (ROCE 15.5%)
- Attractively valued vs sector (P/E 30.2x vs industry 50.2x)
- Virtually debt-free
Concerns
Today's Price Action
The stock closed at ₹1,365.6, unchanged from the previous session. Trading volume registered 9,96,899 shares, exactly matching the 20‑day average, indicating neutral participation and a lack of abnormal buying or selling pressure on the day.
Valuation Snapshot
Cipla’s current P/E of 30.2 stands away from the sector median, which is shown as zero because many peers report losses or have no meaningful earnings. The ROE of 11.6 % reflects moderate profitability, suggesting that the firm generates a reasonable return on shareholders’ equity relative to its capital base.
Key Levels to Watch
The price sits roughly 20 % above the 52‑week low of ₹1,166 and about 15 % below the 52‑week high of ₹1,599, positioning it in the mid‑range of its annual swing. Open‑interest data from the nearest options series shows a modest concentration near the ₹1,300‑₹1,340 strike range, which historically has acted as a minor support‑resistance band for the equity.
Chart Pattern
In the daily candlestick chart, a Bearish Harami appeared two sessions ago, preceded by a Hanging Man six sessions back, while a Bullish Engulfing formed seven sessions ago. These formations collectively signal a recent shift in short‑term momentum, with the Harami and Hanging Man suggesting possible weakening of the prior uptrend, whereas the Engulfing pattern points to a brief reversal of that weakness.
Data Summary
Cipla trades at ₹1,365.6 with a market‑cap figure that is not disclosed in the provided data set. The stock’s valuation metrics—P/E 30.2, P/B 0, and ROE 11.6 %—alongside its 52‑week range of ₹1,166 – ₹1,599, capture the key quantitative snapshot for the current trading day.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,335 | ₹1.0L Cr | 36.6 | 2.87 | 11.2 | 13 | 0.19 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
CIPLA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 33.46% | 33.46% | 30.91% | 30.93% | 29.19% | 29.20% |
| FII | 25.73% | 25.82% | 27.82% | 28.80% | 26.65% | 26.28% |
| DII | 24.05% | 24.15% | 24.66% | 23.95% | 27.49% | 27.89% |
| Public | 16.53% | 16.36% | 16.40% | 16.11% | 16.43% | 16.36% |
| Govt | 0.21% | 0.21% | 0.21% | 0.21% | 0.23% | 0.26% |
Corporate Events
Cipla limited has informed the Exchange about Board Meeting to be held on 27th October, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half-year ended 30th September, 2026.
To consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2026.In terms of the Company's Code of Conduct for prevention of Insider Trading, the 'Trading window' for dealing in the s
Dividend - Rs 13 Per Share
To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share
Dividend - Rs 13 Per Share
Dividend - Rs 8.50 Per Share
Latest News
All newsCipla board meets; no major announcements disclosed
*Cipla board meets; no major announcements disclosed.* The company held its board meeting on October 27, 2026, with no disclosures of significant decisions. No financial results, acquisitions, or leadership changes were announced. Routine board meetings typically precede filings or minor updates. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #BoardMeeting
Cipla reports Q2FY27 financial results
*Cipla reports Q2FY27 financial results*. The company disclosed its quarterly performance with revenue of **₹6,210 crore** and net profit of **₹980 crore**, marking a **12%** and **8%** growth year-on-year. Results reflect steady demand in domestic and international markets. Exports contributed **54%** of total sales. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Cipla reports Q2 FY27 financial results
*Cipla reports Q2 FY27 financial results.* The company announced its financial performance for the quarter ended September 30, 2026. Results include key metrics such as revenue of **₹6,210 crore** and net profit of **₹890 crore**, reflecting growth of **8%** and **12%** year-on-year respectively. Performance driven by strong domestic and international sales. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Cipla announces change in management team
Cipla Limited has announced a change in its management team, as per a regulatory filing with the NSE. Leadership transitions can impact strategic direction and execution in pharma firms. Such changes often trigger investor reassessment of governance and future outlook. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #ManagementChange
Cipla Q2 net profit drops 35% to ₹878 crore
*Cipla Q2 net profit drops 35% to ₹878 crore* due to lower revenue and higher expenses. Revenue declined **2.4% YoY**, missing market expectations. The stock fell sharply post results as investors reacted to the weak performance. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Cipla's USFDA inspects InvaGen facility in New York
*Cipla's USFDA inspects InvaGen facility in New York* — Cipla has announced a routine update regarding a USFDA inspection at its InvaGen manufacturing facility in Hauppauge, Long Island. The inspection is part of regular regulatory compliance checks. No **critical observations** or **adverse findings** have been reported so far. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Regulatory
Cipla grants stock options and stock appreciation rights
*Cipla grants stock options and stock appreciation rights to employees.* The move is part of the company's ongoing employee retention and incentive program. No financial impact is expected in the near term. The details of the grant, including the number of options, were disclosed in an NSE filing. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESOP
Cipla shares unchanged after investor presentation.
*Cipla shares unchanged after investor presentation.* No major announcements on earnings or guidance were made. The presentation detailed ongoing R&D initiatives and portfolio updates. **Q1 FY25 revenue** grew **4% YoY** to **₹6,210 crore**. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Cipla shares unaffected on general corporate updates
*Cipla shares unaffected on general corporate updates.* The company filed routine updates with the NSE, disclosing no major operational or financial changes. Details remain unspecified in the public filing. Investors await clearer signals on growth or regulatory developments. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
Cipla to host analyst and investor meet
*Cipla to host analyst and investor meet.* The event is scheduled as part of its ongoing investor outreach. Details on strategic updates or financial performance may emerge. No immediate business or financial changes announced. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Cipla
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7.1K Cr 6.8% | ₹7.6K Cr 9.1% | ₹7.0K Cr 3.4% | ₹6.7K Cr 4.8% | ₹7.1K Cr 0.3% | ₹7.1K Cr 5.3% | ₹6.7K Cr 8.6% | ₹6.2K Cr |
| Op. Profit | ₹1.3K Cr 33.8% | ₹1.9K Cr 6.6% | ₹1.8K Cr 15.6% | ₹1.5K Cr 22.7% | ₹2.0K Cr 5.5% | ₹1.9K Cr 9.9% | ₹1.7K Cr 30.4% | ₹1.3K Cr |
| OPM | 18.0% 28.0% | 25.0% 3.8% | 26.0% 13.0% | 23.0% 17.9% | 28.0% 3.7% | 27.0% 3.8% | 26.0% 23.8% | 21.0% |
| Net Profit | ₹674 Cr 50.2% | ₹1.4K Cr 4.7% | ₹1.3K Cr 6.4% | ₹1.2K Cr 22.9% | ₹1.6K Cr 20.7% | ₹1.3K Cr 11.1% | ₹1.2K Cr 26.1% | ₹932 Cr |
| EPS (₹) | 8.37 50.0% | 16.73 4.2% | 16.06 6.1% | 15.13 22.2% | 19.45 20.6% | 16.13 10.6% | 14.58 25.4% | 11.63 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28.2K Cr 2.2% | ₹27.5K Cr 6.9% | ₹25.8K Cr 13.3% | ₹22.8K Cr 4.5% | ₹21.8K Cr 13.6% | ₹19.2K Cr 11.8% | ₹17.1K Cr 4.7% | ₹16.4K Cr 8.0% | ₹15.2K Cr 5.3% | ₹14.4K Cr |
| Expenses | ₹22.3K Cr 9.1% | ₹20.4K Cr 4.8% | ₹19.5K Cr 9.9% | ₹17.7K Cr 3.0% | ₹17.2K Cr 15.5% | ₹14.9K Cr 7.0% | ₹13.9K Cr 5.0% | ₹13.3K Cr 7.6% | ₹12.3K Cr 3.6% | ₹11.9K Cr |
| Op. Profit | ₹5.9K Cr 17.5% | ₹7.1K Cr 13.3% | ₹6.3K Cr 25.1% | ₹5.0K Cr 10.4% | ₹4.6K Cr 7.1% | ₹4.3K Cr 32.6% | ₹3.2K Cr 3.5% | ₹3.1K Cr 9.6% | ₹2.8K Cr 13.2% | ₹2.5K Cr |
| OPM | 21.0% 19.2% | 26.0% 8.3% | 24.0% 9.1% | 22.0% 4.8% | 21.0% 4.5% | 22.0% 15.8% | 19.0% 0.0% | 19.0% 0.0% | 19.0% 11.8% | 17.0% |
| Other Income | ₹606 Cr 29.7% | ₹862 Cr 56.2% | ₹552 Cr 88.4% | ₹293 Cr 196.0% | ₹99 Cr 62.8% | ₹266 Cr 22.7% | ₹344 Cr 27.9% | ₹477 Cr 70.4% | ₹280 Cr 34.6% | ₹208 Cr |
| Interest | ₹54 Cr 12.9% | ₹62 Cr 31.1% | ₹90 Cr 18.2% | ₹110 Cr 3.8% | ₹106 Cr 34.2% | ₹161 Cr 18.3% | ₹197 Cr 17.3% | ₹168 Cr 47.4% | ₹114 Cr 28.3% | ₹159 Cr |
| Depreciation | ₹1.2K Cr 9.4% | ₹1.1K Cr 5.3% | ₹1.1K Cr 10.3% | ₹1.2K Cr 11.4% | ₹1.1K Cr 1.5% | ₹1.1K Cr 9.1% | ₹1.2K Cr 11.4% | ₹1.3K Cr 0.2% | ₹1.3K Cr 0.0% | ₹1.3K Cr |
| PBT | ₹5.2K Cr 23.4% | ₹6.8K Cr 19.6% | ₹5.7K Cr 41.2% | ₹4.0K Cr 15.6% | ₹3.5K Cr 6.2% | ₹3.3K Cr 51.1% | ₹2.2K Cr 4.8% | ₹2.1K Cr 24.6% | ₹1.7K Cr 36.6% | ₹1.2K Cr |
| Tax % | 26.0% 18.2% | 22.0% 18.5% | 27.0% 10.0% | 30.0% 11.1% | 27.0% 0.0% | 27.0% 6.9% | 29.0% 7.4% | 27.0% 80.0% | 15.0% 0.0% | 15.0% |
| Net Profit | ₹3.9K Cr 26.7% | ₹5.3K Cr 26.8% | ₹4.2K Cr 46.6% | ₹2.8K Cr 11.2% | ₹2.5K Cr 6.6% | ₹2.4K Cr 59.3% | ₹1.5K Cr 0.5% | ₹1.5K Cr 5.3% | ₹1.4K Cr 36.9% | ₹1.0K Cr |
| EPS (₹) | 48.02 26.4% | 65.28 27.9% | 51.05 47.1% | 34.71 11.3% | 31.19 4.6% | 29.82 55.5% | 19.18 1.2% | 18.96 8.2% | 17.52 40.0% | 12.51 |
| Div Payout | 27.0% 8.0% | 25.0% 0.0% | 25.0% 4.2% | 24.0% 50.0% | 16.0% 5.9% | 17.0% 19.0% | 21.0% 31.3% | 16.0% 5.9% | 17.0% 6.3% | 16.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹162 Cr 0.0% | ₹162 Cr 0.6% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr |
| Reserves | ₹32.8K Cr 5.6% | ₹31.0K Cr 16.9% | ₹26.5K Cr 14.2% | ₹23.2K Cr 12.4% | ₹20.7K Cr 13.8% | ₹18.2K Cr 16.4% | ₹15.6K Cr 5.1% | ₹14.9K Cr 5.6% | ₹14.1K Cr 13.6% | ₹12.4K Cr |
| Borrowings | ₹467 Cr 6.6% | ₹438 Cr 21.6% | ₹559 Cr 30.4% | ₹803 Cr 24.0% | ₹1.1K Cr 47.6% | ₹2.0K Cr 28.5% | ₹2.8K Cr 34.8% | ₹4.3K Cr 5.3% | ₹4.1K Cr 0.4% | ₹4.1K Cr |
| Other Liabilities | ₹6.8K Cr 18.9% | ₹5.7K Cr 8.3% | ₹5.3K Cr 3.5% | ₹5.1K Cr 2.6% | ₹5.0K Cr 9.9% | ₹4.5K Cr 6.8% | ₹4.8K Cr 9.2% | ₹4.4K Cr 2.0% | ₹4.3K Cr 3.2% | ₹4.2K Cr |
| Total Liabilities | ₹40.2K Cr 7.6% | ₹37.3K Cr 14.8% | ₹32.5K Cr 11.0% | ₹29.3K Cr 9.1% | ₹26.9K Cr 8.1% | ₹24.9K Cr 6.1% | ₹23.4K Cr 1.4% | ₹23.8K Cr 4.8% | ₹22.7K Cr 8.6% | ₹20.9K Cr |
Assets | ||||||||||
| Fixed Assets | ₹10.9K Cr 9.3% | ₹10.0K Cr 4.2% | ₹9.6K Cr 4.9% | ₹9.2K Cr 5.4% | ₹9.7K Cr 1.8% | ₹9.5K Cr 1.7% | ₹9.7K Cr 0.8% | ₹9.6K Cr 3.4% | ₹9.9K Cr 4.8% | ₹9.5K Cr |
| CWIP | ₹1.4K Cr 8.2% | ₹1.6K Cr 35.8% | ₹1.2K Cr 5.5% | ₹1.1K Cr 42.7% | ₹766 Cr 20.9% | ₹969 Cr 17.5% | ₹825 Cr 22.0% | ₹676 Cr 31.1% | ₹981 Cr 41.7% | ₹1.7K Cr |
| Investments | ₹8.2K Cr 3.6% | ₹7.9K Cr 45.6% | ₹5.4K Cr 48.8% | ₹3.7K Cr 43.6% | ₹2.6K Cr 5.9% | ₹2.7K Cr 84.2% | ₹1.5K Cr 42.4% | ₹2.6K Cr 102.9% | ₹1.3K Cr 29.4% | ₹973 Cr |
| Other Assets | ₹19.6K Cr 9.8% | ₹17.8K Cr 9.2% | ₹16.3K Cr 6.1% | ₹15.4K Cr 11.0% | ₹13.9K Cr 18.8% | ₹11.7K Cr 1.9% | ₹11.4K Cr 4.8% | ₹10.9K Cr 4.2% | ₹10.5K Cr 20.2% | ₹8.7K Cr |
| Total Assets | ₹40.2K Cr 7.6% | ₹37.3K Cr 14.8% | ₹32.5K Cr 11.0% | ₹29.3K Cr 9.1% | ₹26.9K Cr 8.1% | ₹24.9K Cr 6.1% | ₹23.4K Cr 1.4% | ₹23.8K Cr 4.8% | ₹22.7K Cr 8.6% | ₹20.9K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹5.0K Cr 21.1% | ₹4.1K Cr 27.7% | ₹3.2K Cr 2.6% | ₹3.3K Cr 11.4% | ₹3.8K Cr 22.4% | ₹3.1K Cr 81.4% | ₹1.7K Cr 15.6% | ₹1.5K Cr 38.6% | ₹2.4K Cr 36.8% | ₹1.7K Cr |
| Investing CF | ₹-3.7K Cr 23.5% | ₹-3.0K Cr 25.5% | ₹-2.4K Cr 27.9% | ₹-1.9K Cr 21.7% | ₹-2.4K Cr 2182.5% | ₹114 Cr 106.8% | ₹-1.7K Cr 102.4% | ₹-834 Cr 36.0% | ₹-1.3K Cr 71.2% | ₹-4.5K Cr |
| Financing CF | ₹-1.3K Cr 7.8% | ₹-1.2K Cr 25.3% | ₹-958 Cr 40.1% | ₹-1.6K Cr 29.0% | ₹-1.2K Cr 58.0% | ₹-2.9K Cr 745.0% | ₹-349 Cr 9.4% | ₹-385 Cr 71.0% | ₹-1.3K Cr 142.7% | ₹3.1K Cr |
| Net Cash Flow | ₹30 Cr 161.2% | ₹-49 Cr 49.5% | ₹-97 Cr 26.5% | ₹-132 Cr 193.6% | ₹141 Cr 39.7% | ₹234 Cr 167.8% | ₹-345 Cr 242.0% | ₹243 Cr 198.0% | ₹-248 Cr 179.5% | ₹312 Cr |
| Free Cash Flow | ₹3.5K Cr 23.8% | ₹2.8K Cr 34.1% | ₹2.1K Cr 20.5% | ₹2.6K Cr 10.8% | ₹3.0K Cr 42.3% | ₹2.1K Cr 75.5% | ₹1.2K Cr 64.2% | ₹723 Cr 43.7% | ₹1.3K Cr 86.6% | ₹688 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73d 7.4% | 68d 4.6% | 65d 14.0% | 57d 13.6% | 66d 20.5% | 83d 10.8% | 93d 24.0% | 75d 15.4% | 65d 4.8% | 62d |
| Inventory Days | 231d 6.5% | 217d 4.8% | 228d 0.9% | 230d 0.9% | 232d 13.1% | 267d 6.8% | 250d 7.7% | 271d 13.4% | 239d 12.5% | 273d |
| Days Payable | 116d 13.7% | 102d 8.9% | 112d 3.7% | 108d 4.9% | 103d 25.9% | 139d 13.0% | 123d 13.4% | 142d 31.5% | 108d 1.9% | 106d |
| Cash Conv. Cycle | 188d 3.3% | 182d 0.6% | 181d 0.6% | 180d 7.7% | 195d 7.6% | 211d 4.1% | 220d 7.8% | 204d 4.1% | 196d 14.8% | 230d |
| Working Capital Days | 128d 6.7% | 120d 6.2% | 113d 18.9% | 95d 1.1% | 94d 16.8% | 113d 14.4% | 132d 11.9% | 118d 19.2% | 99d 1090.0% | -10d |
| ROCE | 23.0% 0.0% | 23.0% 27.8% | 18.0% 5.9% | 17.0% 0.0% | 17.0% 41.7% | 12.0% 9.1% | 11.0% 22.2% | 9.0% 28.6% | 7.0% 46.2% | 13.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Cipla Limited
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]
HealthcarePharmaceuticals & Biotechnology